Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Jackson

Psychiatry Boca Raton, FL Medical Doctor

NPI 1508081993 CMS profile 340784

951 Nw 13Th St, Ste 4B, Boca Raton, FL 33486

Open in the dashboard

General payments

$3,609,819

3,871 records reported · program years 2019–2025

Research payments

$24,517

Paid to them · 26 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$450,278 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Richard Jackson of Boca Raton, FL is reported in the CMS Open Payments database as having received $3,609,819 across 3,871 general payments and $24,517 in research payments paid to them. Separately, studies naming them as principal investigator received $450,278 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $817,141 849
2024 General $629,695 658
2023 General $598,887 656
2022 General $515,616 541
2022 Research $1,995 2
2021 General $356,603 319
2021 Research $10,519 9
2020 General $199,878 199
2020 Research $9,306 2
2019 General $491,999 649
2019 Research $2,697 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Jackson
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Richard Jackson were reported at $817,141. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Richard Jackson Psychiatry median Middle half National median
2019 $491,999 $184 $59–$605 $163
2020 $199,878 $119 $36–$372 $114
2021 $356,603 $143 $43–$576 $132
2022 $515,616 $153 $50–$590 $149
2023 $598,887 $170 $56–$651 $160
2024 $629,695 $179 $57–$673 $164
2025 $817,141 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $1,254,092 1,035 payments
  2. Alkermes, Inc. $618,373 580 payments
  3. ITI, Inc. $321,778 310 payments
  4. Otsuka America Pharmaceutical, Inc. $314,872 415 payments
  5. Vanda Pharmaceuticals Inc. $239,664 249 payments
  6. E.R. Squibb & Sons, L.L.C. $209,576 201 payments
  7. Supernus Pharmaceuticals, Inc. $191,064 228 payments
  8. AbbVie, Inc. $94,376 136 payments
  9. Ironshore Pharmaceuticals Inc. $72,592 174 payments
  10. Sunovion Pharmaceuticals Inc. $58,270 82 payments
  11. Other $235,162 461 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,523,631 778 payments
  2. Travel and Lodging $530,122 1,581 payments
  3. Consulting Fee $343,071 81 payments
  4. Food and Beverage $98,021 1,388 payments
  5. Honoraria $93,907 30 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $21,021 12 payments
  7. Education $47 1 payment
Products named General payments · program years 2019–2025
  1. AUSTEDO $773,335 639 payments
  2. Austedo XR $379,135 303 payments
  3. LYBALVI Cns $373,021 354 payments
  4. LYBALVI Cns $352,054 318 payments
  5. LYBALVI Cns $351,826 313 payments
  6. LYBALVI Cns $351,826 313 payments
  7. CAPLYTA $249,672 233 payments
  8. FANAPT $239,664 249 payments
  9. ARISTADA Cns $238,389 264 payments
  10. ARISTADA Cns $238,389 264 payments
  11. Other $2,013,549 2,590 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Purdue Pharma L.P. $12,514 11 payments
  2. Adlon Therapeutics L.P. $9,306 2 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $2,697 13 payments

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

73

Median for Psychiatry & Neurology: 100

Drug cost

$262,261

Median for Psychiatry & Neurology: $2,986

Branded share of claims

64.4%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 23 $241,748
Lybalvi Olanzapine/Samidorphan Malate Brand 12 $18,942
Loxapine Loxapine Succinate Brand 12 $1,285
Olanzapine Generic 11 $152
Lorazepam Generic 15 $135

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
$119,724 23 —
FANAPT
$96,726 — —
LYBALVI
$59,957 12 —
CAPLYTA
$52,485 — —
COBENFY
$40,106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

3,897 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record